Recombinant multi-species FAM9C protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine FAM9C protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene is a member of a gene family which arose through duplication on the X chromosome. The encoded protein may be localized to the nucleus as the protein contains several nuclear localization signals, and has similarity to a synaptonemal complex protein. [provided by RefSeq, Aug 2011]
The Alternative Names of target: FAM9C,Protein FAM9C,TEX39C

Target products collectionGo to FAM9C products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP0830-Ag-1/ GM-Tg-hg-IP0830-Ag-2 Human FAM9C protein Human
GM-Tg-rg-IP0830-Ag-1/ GM-Tg-rg-IP0830-Ag-2 Rat FAM9C protein Rat
GM-Tg-mg-IP0830-Ag-1/ GM-Tg-mg-IP0830-Ag-2 Mouse FAM9C protein Mouse
GM-Tg-cynog-IP0830-Ag-1/ GM-Tg-cynog-IP0830-Ag-2 Cynomolgus/Rhesus macaque FAM9C protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP0830-Ag-1/ GM-Tg-felg-IP0830-Ag-2 Feline FAM9C protein Feline
GM-Tg-cang-IP0830-Ag-1/ GM-Tg-cang-IP0830-Ag-2 Canine FAM9C protein Canine
GM-Tg-bovg-IP0830-Ag-1/ GM-Tg-bovg-IP0830-Ag-2 Bovine FAM9C protein Bovine
GM-Tg-equg-IP0830-Ag-1/ GM-Tg-equg-IP0830-Ag-2 Equine FAM9C protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP0830-Ag-1/ GM-Tg-hg-IP0830-Ag-2; GM-Tg-rg-IP0830-Ag-1/ GM-Tg-rg-IP0830-Ag-2;
GM-Tg-mg-IP0830-Ag-1/ GM-Tg-mg-IP0830-Ag-2; GM-Tg-cynog-IP0830-Ag-1/ GM-Tg-cynog-IP0830-Ag-2;
GM-Tg-felg-IP0830-Ag-1/ GM-Tg-felg-IP0830-Ag-2; GM-Tg-cang-IP0830-Ag-1/ GM-Tg-cang-IP0830-Ag-2;
GM-Tg-bovg-IP0830-Ag-1/ GM-Tg-bovg-IP0830-Ag-2; GM-Tg-equg-IP0830-Ag-1/ GM-Tg-equg-IP0830-Ag-2
Products Name FAM9C protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name FAM9C
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine FAM9C protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.